While some specialties gain efficiencies through the use of physician extenders, such as nurse practitioners and physician assistants, others are unable to leverage these physician extenders, thus limiting their potential for efficiency gains
Protocol 4: nasal spray approach Goal: Needle-free administration with acceptable bioavailability trade-off Duration: 20 days active, then 4-6 months off Schedule: Days 1-20: 10-15 mg epitalon intranasally, divided into 2-3 daily doses Days 21-180: Off cycle Repeat 1-2 times per year Formulation: Reconstitute in saline with 3 percent DMSO for improved nasal absorption
It is not FDA-approved for general therapeutic use in humans, and the World Anti-Doping Agency added it to its Prohibited List in 2022
The Result of the International Symposium at the University of Vienna
[307] We disagree that adding non-conflicting incentives would overwhelm clinicians or reduce the effectiveness of each model
They are truly there to help.